The medicine is a glucagon-like...
You must be logged in to view the whole article.
Click here if you require signing up
Sydbank analyst sees strong competition for Novo Nordisk's Victoza in USA
KineMed to partner with Pfizer to advance new approaches in metabolic disease
FDA okays Amylin's Type 2 diabetes treatment BYDUREON
Novo Nordisk to open Type 1 diabetes R&D centre in Seattle
Bridge Bioresearch gets US patent for CD14 molecule
FDA requests more data from Bristol-Myers Squibb, AstraZeneca over dapagliflozin NDA
Vitae Pharmaceuticals secures USD15m in debt financing
Novartis gains approval for Lucentis, launches Galvus in China
Omni Bio to start new Type 1 diabetes, GVHD trials
NICE recommends Eli Lilly's Bydureon prolonged release exenatide for Type 2 diabetes
Islet Sciences signs product manufacturing deal with NeoStem's PCT
FDA approves Roche's Accu-Chek Nano SmartView blood glucose monitor
Oramed applies for US patent for combined oral therapy of diabetes